Global Antiparasitics Drugs Market – Industry Trends and Forecast to 2030

Analyse et taille du marché des médicaments antiparasitaires

Le marché des médicaments antiparasitaires devrait connaître une croissance significative au cours de la période de prévision. Les approbations de médicaments antiparasitaires par plusieurs autorités réglementaires devraient stimuler la croissance du marché des médicaments antiparasitaires. Les maladies parasitaires touchent principalement les personnes impliquées dans des activités agricoles, domestiques, industrielles et récréatives où l'exposition à l'eau infestée est plus probable. Ces facteurs devraient stimuler la demande de médicaments antiparasitaires. Les approbations des autorités réglementaires pour les médicaments antiparasitaires devraient stimuler le développement du marché des médicaments antiparasitaires.

Data Bridge Market Research analyse le taux de croissance du marché des médicaments antiparasitaires au cours de la période de prévision 2023-2030. Le TCAC attendu du marché des médicaments antiparasitaires a tendance à être d'environ 6 % au cours de la période de prévision mentionnée. Le marché était évalué à 24 milliards USD en 2022 et devrait atteindre 38,25 milliards USD d'ici 2030. En plus des informations sur le marché telles que la valeur marchande, le taux de croissance, les segments de marché, la couverture géographique, les acteurs du marché et le scénario du marché, le rapport de marché organisé par l'équipe de Data Bridge Market Research comprend également une analyse approfondie des experts, une épidémiologie des patients, une analyse du pipeline, une analyse des prix et un cadre réglementaire.

Portée et segmentation du marché des médicaments antiparasitaires

Market Definition

Antiparasitics drugs belong to the specific type of medication meant to treat numerous parasitic diseases such as those caused by parasitic fungi, helminths, ectoparasites, protozoa, amoeba and many others.

Global Antiparasitics Drugs Market Dynamics

Drivers

• Increased Strategic Agreements

There have been several strategic alliances that are helping in the market growth. For instance, in January 2019, Corteva Agriscience, the agriculture division of DowDuPont, and Stoller, a global company focused on plant nutrition foliar and biological solutions, announced a commercial agreement for the exclusive distribution of Rizotec. It is a bionematicide which act against nematode that is caused by parasitic infections in sugarcane crops.

• Increasing Incidence And Awareness of Parasitic Infections

As per the statistics of the World Health Organization (WHO), April 2022, about 6-7 million people were diagnosed with Chagas Disease, which is a parasitic infection caused by the Trypanosoma cruzi parasite. Furthermore, the WHO announced a series of guidelines in June 2020 to control Schistosomiasis, a parasitic neglected tropical disease, to eradicate it as a public health problem by 2025 and make the world a "World Free Schistosomiasis”.

Opportunities

• Increased Product Launches

Growing product launches and approvals by several market players are projected to drive the antiparasitic drugs market growth during the forecast period. For instance, in August 2021, ParaPRO, which is a specialty pharmaceutical company is focused on innovative anti-parasitic treatments, announced the launch of Natroba Topical Suspension, 0.9 %, for scabies treatment. The supplemental New Drug Application (sNDA) for Natroba, which is a focused topical treatment for scabies infestations in adult and pediatric patients 4 years of age and above, was approved by the US FDA in April 2021.  Thus, these factors expand the market.  

• Increasing Approval Rates

The researchers dealing with potential antimalarial drugs are developing the most promising candidates. Additionally, in May 2021, Bajaj Healthcare launched its new anti-parasitic drug, Ivejaj, that can be used for COVID treatment. The company has received approval from India’s drug regulator, DCGI, to manufacture and market the tablets. Thus, these factors are growing the market.

 Restraints/Challenges

• Lack of Awareness

The lack of awareness about these disorders and the unavailability of numerous awareness programs impede the market growth. The available drugs have not shown disease-modifying activity and are still mostly insufficient for managing major unmet needs.

• High Cost

The huge expenditure associated with these agents hamper the market growth. Increasing cost of the antiparasitic drugs is projected to hinder the market growth during the forecast period. For instance, according to the records of the American Journal of Tropical Medicine and Hygiene, 2021, the increasing price of pharmaceuticals in the U.S., that  are used to treat three soil-transmitted helminth infections, hookworm, roundworm, and whipworm has led to increase in total treatment for patients with Medicaid or private insurance.

This global antiparasitics drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global antiparasitics drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impacts on Global Antiparasitics Drugs Market

The demand for treating COVID-19 with numerous drugs, such as antiviral and anti-parasitic, observed a significant boost in 2021. Several clinical trials were undertaken to see the effect of these drugs on novel coronavirus. The most effective drug among the anti-parasitic drug classes was Ivermectin, that was approved by the U.S. FDA for the therapeutic use among coronavirus patients. Similarly, as per the National Center for Biotechnology Information data, in April 2021, Ivermectin, an anti-parasitic drug, limited the SARS-CoV-2 virus growth by removing all the viral RNA from growing in cell culture within 48 hours. Thus, initially, the growth of the anti-parasitic drugs market was hindered because of the government's restrictions on the COVID-19 pandemic. But, the market is projected to gain traction because of the growing demand for antiparasitic drugs for treating COVID-19 patients and the growth in the number of drug trials for COVID-19 treatment.

Global Antiparasitics Drugs Market Scope

The global antiparasitics drugs market is segmented on the basis of treatment, route of administration, therapeutics categories, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Therapeutic Categories

• Antinematodal
• Anticestodal
• Antilung Worm
•  Antifilarial
• Antiprotozoal
• Insecticide

Treatment

• Avermectins
• Bezimidazoles
• Pyrimidines
• Organophosphates
• Imidazolesthiazoles

Route of Administration

• Oral
• Parenteral
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

 Antiparasitics Drugs Market Regional Analysis/Insights

The global antiparasitics drugs market is analyzed and market size insights and trends are provided by treatment, route of administration, therapeutics categories, distribution channel and end-user as referenced above.

The major countries covered in the global antiparasitics drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing positive growth for global antiparasitics drugs market throughout the forecasted period due to the increased prevalence of antiparasitics, high demand for targeted therapies, and advanced healthcare facilities.

North America dominates the market due to increasing disease awareness and rapidly disposable income.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Antiparasitics Drugs Market Share Analysis

The global antiparasitics drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global antiparasitics drugs market.

Key players operating in the global antiparasitics drugs market include:

• Pfizer Inc (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Mylan N.V. (U.S.)
• Fresenius Kabi AG (Germany)
• Hikma Pharmaceuticals PLC (U.K.)
• Novartis AG (Switzerland)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Bristol Myers Squibb Company (U.S.)
• GSK Plc. (U.K.)
• Bayer AG (Germany)
• Sun Pharmaceutical Industries Ltd (India)
• Boehringer Ingelheim International Gmbh (Germany)
• Sanofi (France)
• Arbor Pharmaceuticals, Inc (U.S.)
• Alkem Labs Ltd (India)

Research Methodology: Global Antiparasitics Drugs Market           

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.

SKU-55898